SCHEMBL31136618

SCHEMBL31136618

O=C1CC2(CC2)c2cc(C(F)(F)F)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 2/20 0.46
PARP1 P09874 1/20 0.40
PARP10 Q53GL7 1/20 0.40
HTR2A P28223 2/20 0.37
HTR2C P28335 2/20 0.37
HTR2B P41595 2/20 0.37
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
APP P05067 1/20 0.34
GPR3 P46089 1/20 0.33
FABP4 P15090 1/20 0.33
DAO P14920 1/20 0.33
BACE1 P56817 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
JUN P05412 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24457584 0.76 PARP10 (0.50) TDP2PARP1PARP10HTR2AHTR2C
SCHEMBL30643108 0.74 TDP2 (0.42) TDP2PARP1PARP10HTR2AHTR2C
SCHEMBL31064284 0.73 TDP2 (0.43) TDP2PARP1PARP10HTR2AHTR2C
SCHEMBL16154733 0.70 ALDH1A1 (0.42) ALDH1A1NFKB1NFKB2RELA
SCHEMBL31040915 0.70 TDP2 (0.43) TDP2PARP1PARP10PIM1PIM3
SCHEMBL4426124 0.70 PGR (0.62) TDP2PARP1PARP10APPALDH1A1
SCHEMBL31040917 0.70 TDP2 (0.43) TDP2PARP1PARP10PIM1PIM3
SCHEMBL30953576 0.69 KDM4E (0.54) TDP2ALDH1A1SIGMAR1
SCHEMBL30953777 0.69 KDM4E (0.50) TDP2ALDH1A1SIGMAR1
SCHEMBL3593417 0.69 KDM4E (0.50) TDP2ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 TDP2 537/4885PARP1 176/4885PARP10 232/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 TDP2 162/4885PARP1 233/4885PARP10 136/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 TDP2 162/4885PARP1 233/4885PARP10 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.